Contract 75D30125D00198
Glaxosmithkline, Llc · Department Of Health And Human Services · July 25, 2025
Glaxosmithkline, Llc was awarded a federal contract by Department Of Health And Human Services (Centers For Disease Control And Prevention) on July 25, 2025 for $457.96 million of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses order dependent (idv allows pricing arrangement to be determined separately for each order) contract pricing. The most recent modification was on February 5, 2026. If all options are exercised, the contract could reach $1.49 billion.
Contract details
- PIID
- 75D30125D00198
- Award type
- —
- Pricing
- Order Dependent (Idv Allows Pricing Arrangement To Be Determined Separately For Each Order)
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- July 25, 2025
- Latest action
- February 5, 2026
Description
VACCINES FOR CHILDREN FY25
Modification timeline
-
February 5, 2026Mod P00006 · Funding Only Action$793.02M
-
October 31, 2025Mod P00005 · Funding Only Action$793.02M
-
August 27, 2025Mod P00004 · Funding Only Action$793.02M
-
July 25, 2025Mod P00003 · Other Administrative Action$793.02M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Merck Sharp & Dohme Llc | Department Of Health And Human Services | March 27, 2026 | $361.34M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75D30125D00198?
Contract 75D30125D00198 is a federal contract awarded to Glaxosmithkline, Llc by Department Of Health And Human Services on July 25, 2025 for $457.96 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 3 times since the base award.
Who won contract 75D30125D00198?
Glaxosmithkline, Llc won contract 75D30125D00198 from Department Of Health And Human Services.
How much is contract 75D30125D00198 worth?
Contract 75D30125D00198 has obligated $457.96 million to date, with a total potential value of $1.49 billion if all options are exercised.